Trial Profile
A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2014
Price :
$35
*
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Therapeutic Use
- Sponsors Zymenex A/S
- 19 May 2014 New trial record